WHO WE ARE
Our mission is to overcome the challenge of delivery to allow the full potential of gene therapy to be realised
NanoGenics is an innovative, research-based biotechnology company leading the development of artificial viruses to deliver gene therapy.
For too long, the promise of gene therapy has been held back by practical limitations – whether the complex manufacturing, expense, and toxicity of viral vectors, or the limited efficacy of traditional liposomes. Our novel artificial virus, LipTide, is designed to overcome these issues, bringing us one step closer to delivering the full benefit of targeted gene therapy. The LipTide technology was invented at University College London (UCL). UCL Business, the Technology Transfer Organisation for UCL have retained equity in the company and are business partners.
To achieve this vision, NanoGenics is developing a series of in-house products using the LipTide platform across a range of disease areas from cancer to cystic fibrosis. Our lead product will enter clinical trials in 2020.
The versatility and specificity of LipTide means we would be ideal partners to help deliver your payloads, whether mRNA, DNA, siRNA or miRNA. Please contact us to find out more about our personalised approach to creating a customised LipTide particle just for you.